Cel-Sci Corp (CVM)

Jan 14, 2025, 9:00 AM EST - 5 days ago

CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer

Dec 31, 2024, 4:05 PM EST - 18 days ago

CEL-SCI Announces Closing of $5 Million Offering

Dec 29, 2024, 8:41 PM EST - 20 days ago

CEL-SCI Announces Pricing of $5 Million Public Offering

Dec 27, 2024, 5:05 PM EST - 22 days ago

CEL-SCI Announces Proposed Public Offering of Common Stock

Dec 12, 2024, 9:15 AM EST - 5 weeks ago

CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study

Nov 8, 2024, 8:00 AM EST - 2 months ago

Stock Picks From Seeking Alpha's October 2024 New Analysts

ACGL AMCX AMPS APOG AVRE BHP BILL

Nov 7, 2024, 8:15 AM EST - 2 months ago

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

Oct 22, 2024, 9:15 AM EDT - 3 months ago

FDA's Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI's Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients

Oct 1, 2024, 6:00 AM EDT - 3 months ago

CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer

Sep 16, 2024, 7:30 AM EDT - 4 months ago

CEL-SCI's Multikine® Increased 5-Year Survival Rate to 82.6% in Locally Advanced Resectable Head & Neck Cancer Patients Who Were Deemed to be in the Treatment Group for Surgery and Radiation

Sep 10, 2024, 9:32 AM EDT - 4 months ago

CEL-SCI to Present New Data for Multikine® Head & Neck Cancer Immunotherapy at the European Society for Medical Oncology 2024 Congress

Sep 4, 2024, 9:00 AM EDT - 4 months ago

The UK's Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance

Aug 15, 2024, 8:00 AM EDT - 5 months ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results

Jul 29, 2024, 4:05 PM EDT - 6 months ago

CEL-SCI Announces Closing of $10.8 Million Offering

Jul 26, 2024, 11:52 AM EDT - 6 months ago

CEL-SCI Announces Pricing of $10.8 Million Offering

Jul 26, 2024, 8:23 AM EDT - 6 months ago

CEL-SCI's Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

Jul 8, 2024, 9:15 AM EDT - 6 months ago

CEL-SCI Appoints Robert Watson as Chairperson of the Board

Jun 18, 2024, 8:00 AM EDT - 7 months ago

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

Jun 6, 2024, 7:00 AM EDT - 8 months ago

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

May 16, 2024, 9:00 AM EDT - 8 months ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 8, 2024, 9:00 AM EDT - 9 months ago

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

Apr 23, 2024, 9:00 AM EDT - 9 months ago

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

Apr 16, 2024, 9:00 AM EDT - 9 months ago

Channel V Media Expands Content Marketing Division; Names Gabriella Bock Director of Content

Mar 19, 2024, 9:00 AM EDT - 10 months ago

CEL-SCI's LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

Mar 6, 2024, 8:45 AM EST - 11 months ago

CEL-SCI Corporation Issues Letter to Shareholders

Feb 15, 2024, 8:00 AM EST - 1 year ago

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

Feb 13, 2024, 12:00 PM EST - 1 year ago

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

Feb 9, 2024, 8:30 AM EST - 1 year ago

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

Feb 6, 2024, 9:00 AM EST - 1 year ago

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

Jan 31, 2024, 9:00 AM EST - 1 year ago

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

Dec 22, 2023, 8:00 AM EST - 1 year ago

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

Dec 4, 2023, 8:30 AM EST - 1 year ago

UK'S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI's Multikine as Potential New Standard of Care for Head & Neck Cancer

Nov 20, 2023, 4:15 PM EST - 1 year ago

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

Nov 16, 2023, 8:30 AM EST - 1 year ago

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

Oct 30, 2023, 9:20 AM EDT - 1 year ago

CEL-SCI Issues Letter to Shareholders

Oct 24, 2023, 8:00 AM EDT - 1 year ago

CEL-SCI Releases Video Detailing Recent Phase 3 Findings & its Plans to Seek Immediate Regulatory Approvals

Oct 23, 2023, 9:15 AM EDT - 1 year ago

5-Year Head & Neck Cancer Survival Increased From 45% to 73% in CEL-SCI's Target Population, Cutting Risk of Death in Half, as Presented at Leading Cancer Conference ESMO 2023

Oct 19, 2023, 8:00 AM EDT - 1 year ago

CEL-SCI Readies Its Multikine Manufacturing Facility for Commercial Scale Production

Oct 5, 2023, 8:45 AM EDT - 1 year ago

CEL-SCI Files Request With the UK's MHRA Regarding Path to Approval for Multikine in the Treatment of Head & Neck Cancer

Sep 26, 2023, 9:00 AM EDT - 1 year ago

CEL-SCI Submits Scientific Advice Filing to European Medicines Agency (EMA) for Multikine in the Treatment of Head & Neck Cancer

Aug 11, 2023, 8:00 AM EDT - 1 year ago

CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results

Jul 20, 2023, 11:36 AM EDT - 1 year ago

CEL-SCI Announces Closing of Public Offering

Jul 17, 2023, 9:23 PM EDT - 1 year ago

CEL-SCI Announces Pricing of Public Offering

Jul 14, 2023, 9:15 AM EDT - 1 year ago

CEL-SCI Concludes Positive Meeting With U.S. FDA Concerning Multikine's Approval for Head & Neck Cancer

Jul 11, 2023, 8:45 AM EDT - 1 year ago

CEL-SCI Reports Phase 3 Tumor PD-L1 Biomarker Data Demonstrate Multikine's Increased Efficacy and Points to Potential for Combination With Checkpoint Inhibitors for Head & Neck Cancer

Jun 22, 2023, 10:19 AM EDT - 1 year ago

CEL-SCI to Present Novel Data at AHNS 11th International Conference on Head and Neck Cancer—New Patent to Be Filed

May 15, 2023, 9:00 AM EDT - 1 year ago

Histopathology and Tumor Biomarker Analysis Confirm CEL-SCI's Multikine Significantly Prolonged Overall Survival in Head & Neck Cancer—Phase 3 Data Presented at ESTRO 2023

May 12, 2023, 4:30 PM EDT - 1 year ago

CEL-SCI Corporation Reports Second Quarter Fiscal 2023 Financial Results

Apr 27, 2023, 9:12 PM EDT - 1 year ago

CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock

Apr 19, 2023, 9:00 AM EDT - 1 year ago

CEL-SCI to Pursue Canada's Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer